Targeting α-synuclein for treatment of Parkinson's disease: Mechanistic and therapeutic considerations

The Lancet Neurology

Volumn 14, Issue 8, 2015, Pages 855-866

  Dehay, Benjamin ^a   Bourdenx, Mathieu ^a   Gorry, Philippe ^b   Przedborski, Serge ^c   Vila, Miquel ^d,e,f   Hunot, Stéphane ^g,h,i   Singleton, Andrew ^j   Olanow, C Warren ^k   Merchant, Kalpana M ^l   Bezard, Erwan ^a   Petsko, Gregory A ^m   Meissner, Wassilios G ^a  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g SORBONNE UNIVERSITÉ   (France)

^h CNRS   (France)

ⁱ INSERM   (France)

^j NATIONAL INSTITUTE ON AGING   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l TransThera Consulting   (United States)

^m FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT;

ALZHEIMER DISEASE; BRAIN STEM; CELL LOSS; DRUG TARGETING; GENE; GENE MUTATION; HUMAN; LEWY BODY; MESENCEPHALON; NERVE CELL; NERVE DEGENERATION; NEURITE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NOTE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; SNCA GENE; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; METABOLISM;

ALPHA-SYNUCLEIN; ANIMALS; DRUG DISCOVERY; HUMANS; PARKINSON DISEASE;

EID: 84937516707     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00006-X     Document Type: Note

References (121)

1. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011, 10:377-393.
2. Lashuel HA, Overk CR, Oueslati A, Masliah E The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013, 14:38-48.
3. Jankovic J Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
6. Goedert M, Spillantini MG, Del Tredici K, Braak H 100 years of Lewy pathology. Nat Rev Neurol 2013, 9:13-24.
7. Tretiakoff C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. PhD thesis, University of Paris, 1919.
8. Uéda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:11282-11286.
9. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
10. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
11. Lesage S, Anheim M, Letournel F, et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013, 73:459-471. the French Parkinson's Disease Genetics Study Group.
12. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
13. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.
14. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013, 28:811-813.
15. Proukakis C, Dudzik CG, Brier T, et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013, 80:1062-1064.
16. Pasanen P, Myllykangas L, Siitonen M, et al. Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging 2014, 35:e1-e5.
17. Seidel K, Schöls L, Nuber S, et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol 2010, 67:684-689.
18. Kotzbauer PT, Giasson BI, Kravitz AV, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2004, 187:279-288.
19. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
20. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
21. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014, 46:989-993. the International Parkinson's Disease Genomics Consortium (IPDGC), the Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI)the Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), the 23andMethe 23andMe, the GenePDthe GenePD, the NeuroGenetics Research Consortium (NGRC)the NeuroGenetics Research Consortium (NGRC), the Hussman Institute of Human Genomics (HIHG)the Hussman Institute of Human Genomics (HIHG), the Ashkenazi Jewish Dataset Investigatorthe Ashkenazi Jewish Dataset Investigator, the Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE)the Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE), the North American Brain Expression Consortium (NABEC)the North American Brain Expression Consortium (NABEC), the United Kingdom Brain Expression Consortium (UKBEC)the United Kingdom Brain Expression Consortium (UKBEC), the Greek Parkinson's Disease Consortiumthe Greek Parkinson's Disease Consortium, the Alzheimer Genetic Analysis Groupthe Alzheimer Genetic Analysis Group.
22. Bendor JT, Logan TP, Edwards RH The function of α-synuclein. Neuron 2013, 79:1044-1066.
23. Rochet JC, Hay BA, Guo M Molecular insights into Parkinson's disease. Prog Mol Biol Transl Sci 2012, 107:125-188.
24. Giasson BI, Murray IV, Trojanowski JQ, Lee VM A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001, 276:2380-2386.
25. Wang W, Perovic I, Chittuluru J, et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 2011, 108:17797-17802.
26. Bartels T, Choi JG, Selkoe DJ α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
27. Gould N, Mor DE, Lightfoot R, Malkus K, Giasson B, Ischiropoulos H Evidence of native α-synuclein conformers in the human brain. J Biol Chem 2014, 289:7929-7934.
28. Fauvet B, Mbefo MK, Fares MB, et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 2012, 287:15345-15364.
29. Conway KA, Harper JD, Lansbury PT Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4:1318-1320.
30. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000, 97:571-576.
31. Karpinar DP, Balija MB, Kügler S, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J 2009, 28:3256-3268.
32. Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 2011, 108:4194-4199.
33. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012, 149:1048-1059.
34. Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007, 27:9220-9232.
35. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004, 279:4625-4631.
36. Volles MJ, Lansbury PT Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41:4595-4602.
37. Quist A, Doudevski I, Lin H, et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 2005, 102:10427-10432.
38. van Rooijen BD, Claessens MM, Subramaniam V Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism. PLoS One 2010, 5:e14292.
39. Freeman D, Cedillos R, Choyke S, et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013, 8:e62143.
40. Choi BK, Choi MG, Kim JY, et al. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA 2013, 110:4087-4092.
41. Okochi M, Walter J, Koyama A, et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 2000, 275:390-397.
42. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002, 4:160-164.
43. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006, 281:29739-29752.
44. Paleologou KE, Schmid AW, Rospigliosi CC, et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 2008, 283:16895-16905.
45. Kellie JF, Higgs RE, Ryder JW, et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep 2014, 4:5797.
46. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
47. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001, 294:1346-1349.
48. Norris EH, Giasson BI, Ischiropoulos H, Lee VM Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003, 278:27230-27240.
49. Yamin G, Uversky VN, Fink AL Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 2003, 542:147-152.
50. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007, 27:3338-3346.
51. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 2010, 32:409-422.
52. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM Degradation of alpha-synuclein by proteasome. J Biol Chem 1999, 274:33855-33858.
53. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003, 278:25009-25013.
54. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
55. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
56. Bieschke J, Russ J, Friedrich RP, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 2010, 107:7710-7715.
57. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008, 118:777-788.
58. Winslow AR, Chen CW, Corrochano S, et al. α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol 2010, 190:1023-1037.
59. Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VM Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy. J Biol Chem 2013, 288:15194-15210.
60. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, et al. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci 2011, 31:14508-14520.
61. Dehay B, Bové J, Rodríguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010, 30:12535-12544.
62. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis 2009, 35:385-398.
63. Bellucci A, Navarria L, Zaltieri M, et al. Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J Neurochem 2011, 116:588-605.
64. Guardia-Laguarta C, Area-Gomez E, Rüb C, et al. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 2014, 34:249-259.
65. Mattson MP, Magnus T Ageing and neuronal vulnerability. Nat Rev Neurosci 2006, 7:278-294.
66. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008, 14:504-506.
67. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008, 14:501-503.
68. Mendez I, Viñuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008, 14:507-509.
69. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
70. Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014, 75:351-362.
71. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
72. Recasens A, Dehay B Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014, 8:159.
73. Bousset L, Pieri L, Ruiz-Arlandis G, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013, 4:2575.
74. Kim C, Ho DH, Suk JE, et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013, 4:1562.
75. Hirsch EC, Hunot S Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
76. Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2008, 3:e1376.
77. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119:182-192.
78. Schapira AH, Olanow CW, Greenamyre JT, Bezard E Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014, 384:545-555.
79. Gorbatyuk OS, Li S, Nash K, et al. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther 2010, 18:1450-1457.
80. Khodr CE, Sapru MK, Pedapati J, et al. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 2011, 1395:94-107.
81. Khodr CE, Becerra A, Han Y, Bohn MC Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res 2014, 1550:47-60.
82. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 2010, 5:e12122.
83. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467:179-184.
84. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 2009, 4:e5515.
85. Spencer B, Potkar R, Trejo M, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 2009, 29:13578-13588.
86. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci USA 2013, 110:E1817-E1826.
87. Xilouri M, Brekk OR, Landeck N, et al. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain 2013, 136:2130-2146.
88. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 2010, 30:1166-1175.
89. Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, et al. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis 2010, 39:423-438.
90. Oueslati A, Schneider BL, Aebischer P, Lashuel HA Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci USA 2013, 110:E3945-E3954.
91. Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci 2011, 31:6963-6971.
92. Diepenbroek M, Casadei N, Esmer H, et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice. Hum Mol Genet 2014, 23:3975-3989.
93. Auluck PK, Bonini NM Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 2002, 8:1185-1186.
94. Lo Bianco C, Shorter J, Régulier E, et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 2008, 118:3087-3097.
95. Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol 2013, 125:795-813.
96. Levin J, Schmidt F, Boehm C, et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 2014, 127:779-780.
97. Prabhudesai S, Sinha S, Attar A, et al. A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 2012, 9:464-476.
98. Savolainen MH, Richie CT, Harvey BK, Männistö PT, Maguire-Zeiss KA, Myöhänen TT The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol Dis 2014, 68:1-15.
99. Myöhänen TT, Hannula MJ, Van Elzen R, et al. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br J Pharmacol 2012, 166:1097-1113.
100. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6:e19338.
101. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol 2014, 127:861-879.
102. Tran HT, Chung CH, Iba M, et al. α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep 2014, 7:2054-2065.
103. Bezard E, Yue Z, Kirik D, Spillantini MG Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord 2013, 28:61-70.
104. Bové J, Martínez-Vicente M, Vila M Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 2011, 12:437-452.
105. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007, 282:5641-5652.
106. Castillo K, Nassif M, Valenzuela V, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 2013, 9:1308-1320.
107. Sato H, Arawaka S, Hara S, et al. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 2011, 31:16884-16894.
108. Chen L, Feany MB Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005, 8:657-663.
109. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 2004, 279:25497-25502.
110. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012, 32:13454-13469.
111. Fuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008, 22:1327-1334.
112. Pareja ME, Colombo MI Autophagic clearance of bacterial pathogens: molecular recognition of intracellular microorganisms. Front Cell Infect Microbiol 2013, 3:54.
113. Zhou C, Przedborski S Intrabody and Parkinson's disease. Biochim Biophys Acta 2009, 1792:634-642.
114. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333. the Bapineuzumab 301 and 302 Clinical Trial Investigators.
115. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321. the Alzheimer's Disease Cooperative Study Steering Committee, the Solanezumab Study Groupthe Solanezumab Study Group.
116. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.
117. Lee VM, Brunden KR, Hutton M, Trojanowski JQ Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 2011, 1:a006437.
118. Lim Y, Kehm VM, Lee EB, et al. α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011, 31:10076-10087.
119. Fernagut PO, Dehay B, Maillard A, et al. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis 2014, 67:133-139.
120. Fanciulli A, Wenning GK Multiple-system atrophy. N Engl J Med 2015, 372:249-263.
121. Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials. Neurology 2015, 84:1104-1113.